Intensidade da dor após aplicação de somatropina humana recombinante: estudo comparativo de não-inferioridade, randomizado e cruzado/Pain intensity after application of recombinant human somatropin: a comparative study of non-inferiority, randomized and crossed [PDF]
, 2020 Objetivo: Baixa estatura patológica é uma condição idiopática na faixa etária pediátrica, com consequências psicológicas e cardiometabólicas. A adesão é um fator determinante para o sucesso no tratamento da deficiência de hormônio do crescimento, e a ...
Amato, Florencia +10 more
core +1 more source
Les enjeux des biosimilaires, du modèle économique à la valorisation [PDF]
, 2015 Contient en annexe un article en français de 3 p. intitulé : Valorisation d’un produit « Biosimilaire »Like what happened in the classical pharmaceutical market, namely a weak productivity in R&D and the fallout of blockbusters patents, the biotechnology
Duffaud, Maxime
core +1 more source
Ongoing development of guidelines for biosimilar medicines assessment in Uganda: Critical evaluation and recommendations for inclusion [PDF]
, 2020 >Magister Scientiae - MScA Biosimilar is defined as a biologic product that is similar but not identical to the reference/originator biologic product.
Nantongo, Eva
core
Biosimilars in der Schweiz : Medizin gegen die steigenden Gesundheitskosten? [PDF]
, 2020 Kobler, Irene +5 more
core +1 more source
Biosimilars approvals by thirteen regulatory authorities: A cross-national comparison [PDF]
, 2023 Acosta Angela +14 more
core +1 more source
Razvoj i odobravanje biosličnih lijekova u Europskoj uniji [PDF]
, 2016 CILJ ISTRAŽIVANJA: Cilj je ovog specijalističkog rada sustavnim pregledom dostupne literature prikazati specifičnosti razvoja i odobravanja biosličnog lijeka u Europskoj uniji prema znanstveno-regulatornom principu usporedivosti s referentnim biološkim ...
Sokol, Petra
core +1 more source
Long-Term Real-World Post-approval Safety Data of Multiple Biosimilars from One Marketing-Authorization Holder After More than 18 Years Since Their First Biosimilar Launch. [PDF]
Drug Saf, 2023 Sagi S +4 more
europepmc +1 more source
Los medicamentos biológicos y biosimilares: fabricación y autorización en la Unión Europea [PDF]
24 p.: il. -- Bibliogr.: p. 20-24Los medicamentos biológicos, a diferencia de los medicamentos químicos convencionales (moléculas pequeñas con estructuras simples, características definidas y perfectamente reproducibles) son medicamentos complejos ...
Merino García, Imanol
core
La sostenibilita' dei trattamenti ad alto costo: il caso dell'ormone della crescita [PDF]
, 2016 Over last decades, National Health Systems found themselves involved in an ever more complex reality. Population growth, quality of life and life expectancy improvement are challenging their sustainability.
Naccari, Francesca
core +1 more source
Spotlight on Lonapegsomatropin Once-Weekly Injection and Its Potential in the Treatment of Growth Hormone Deficiency in Pediatric Patients. [PDF]
Drug Des Devel Ther, 2022 Miller BS, Yuen KCJ.
europepmc +1 more source